Skip to main content

Table 1 Characteristics of the included RCTs

From: Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis

References

Kwon et al. [14]

Kim et al. [15]

Zhu et al. [16]

ARTIST 2012/2015

Characteristics

CRT

CT

CRT

CT

CRT

CT

CRT

CT

Patient number

31

30

46

44

186

165

230

228

Age year

56 (23–73)

49 (29–70)

>60, (19.6 %)

>60, (31.8 %)

56 (38–73)

59 (42–75)

56 (28–76)

56 (22–77)

Sex no. (%)

 Male

21 (67.7)

23 (76.7)

34 (73.9)

25 (56.8)

135 (72.9)

126 (76.4)

143 (62.2)

153 (67.1)

 Female

10 (32.3)

7 (23.3)

12 (26.1)

19 (43.2)

51 (27.1)

39 (23.6)

87 (37.8)

75 (32.9)

ECOG PS no. (%)

        

 0

NR

NR

35 (76.1)

27 (61.4)

NR

NR

99 (43.0)

96 (42.1)

 1

NR

NR

11 (23.9)

17 (38.6)

NR

NR

131 (57.0)

132 (57.9)

Primary tumor site no. (%)

 Proximal

6 (16.1)

4 (13.3)

3 (6.5)

2 (4.5)

30 (16.1)

15 (9.1)

13 (5.7)

9 (3.9)

 Body

9 (29.0)

11 (36.7)

26 (56.5)

19 (43.2)

21 (11.3)

33 (20)

107 (46.5)

112 (49.1)

 Antrum

17 (54.8)

15 (50.0)

14 (30.5)

18 (40.9)

135 (72.6)

117 (70.9)

90 (39.1)

87 (38.2)

 Multiple/diffuse

0

0

3 (6.5)

5 (11.4)

0

0

20 (8.7)

20 (8.8)

Laurén’s classification no. (%)

 Intestinal

5 (16.1)

12 (40.0)

16 (34.8)

15 (34.1)

NR

NR

75 (32.6)

88 (38.6)

 Diffuse

20 (64.4)

13 (43.3)

26 (56.5)

24 (54.5)

NR

NR

144 (62.6)

130 (57.0)

 Mixed/unclassified

6 (19.4)

5 (16.7)

4 (8.6)

5 (11.3)

NR

NR

11 (4.8)

10 (4.4)

Tumor stage no. (%)

 Ib

0

0

0

0

20 (10.8)

15 (9.1)

49 (21.3)

50 (21.9)

 II

0

0

0

0

36 (19.4)

30 (18.2)

84 (36.5)

86 (37.7)

 III

24 (77.4)

27 (90.0)

34 (73.9)

31 (75.0)

103 (55.4)

96 (58.2)

71 (30.8)

65 (28.6)

 IV (M0)

7 (22.6)

3 (10)

12 (26.1)

11 (25.0)

27 (14.5)

24 (14.5)

26 (11.3)

27 (11.8)

 pN+

NR

NR

46 (100)

42 (95.5)

158 (84.9)

143 (86.7)

203 (88.2)

193 (84.6)

Lymphadenectomy

D2

D2

D2

D2

Treatment regimens

FP/RT

FP

FL/RT

FL

FL/IMRT

FL

XP/XRT/XP

XP

Total RT dose/technique

45 Gy/3D-CRT

45 Gy/AP-PA fields

45 Gy/IMRT

45 Gy/AP-PA fields

Endpoints

3-ys DFS: 80.0 % vs 75.2 %; P = 0.887

5-ys DFS: 76.7 % vs 59.1 %; P = 0.222

5-ys OS: 70.1 % vs 70.0 %; P = 0.814

5-ys DFS: 60.9 % vs 50.0 %; P = 0.246

5-ys OS: 65.2 % vs 54.6 %; P = 0.67

5-ys RFS: 45.2 % vs 35.8 %, P = 0.029

5-ys OS: 48.4 % vs 41.8 %, P = 0.122

3-ys DFS: 78.2 % vs 74.2 %; P = 0.0862

7-ys DFS: P = 0.740

5-ys OS: 75 % vs 73 %; P = 0.484

Median follow-up months

77.2 (24–92.8)

86.7 (60.3–116.5)

42.5

2012: 53.2(36.9–77.3)

2015: 7 years

  1. FP regimen: 5-Fu 1000 mg/m2 continuous infusion on days 1–5, cisplatin 60 mg/m2 on day 1 every 3 weeks, totally 6 cycles; FP/RT: 1 cycle of FP, then RT (45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with continuous capecitabine 825 mg/m2 twice daily during radiotherapy), followed by 3 cycles of FP; FL regimen: 5-Fu 425 mg/m2, leucovorin 20 mg/m2, for 5 days with a 4-week interval, totally 5 cycles; FL/RT: 1 cycle of FL, then RT (45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with 2 cycles of FL), followed by 2 cycles of FL; XP regimen: capecitabine 1000 mg/m2 twice daily on days 1 to 14; cisplatin 60 mg/m2 on day 1 every 3 weeks, totally 6 cycles; XP/XRT/XP: 2 cycles of XP, then XRT (45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with continuous capecitabine 825 mg/m2 twice daily during radiotherapy), followed by 2 cycles of XP
  2. CT chemotherapy, CRT chemoradiotherapy, NR not reported, 3-ys DFS 3-year disease-free survival, 5-ys DFS 5-year disease-free survival, 5-ys OS 5-year overall survival, 3D-CRT 3D conformal radiotherapy, IMRT intensity-modulated radiotherapy, LN lymph node